Comparative Efficacy and Safety of Antidiabetic Drug Regimens Added to Metformin Monotherapy in Patients with Type 2 Diabetes: A Network Meta-Analysis

Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial

(2014) Hans-Ulrich Häring et al.   DIABETES CARE

Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)

(2014) Michael Nauck et al.   DIABETES CARE

Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis

(2014) William L. Baker et al.   Journal of the American Society of Hypertension

Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients

(2014) Giuseppe Derosa et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy

(2014) Judith L White et al.   BMC Endocrine Disorders

Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial

(2014) Martin Ridderstråle et al.   Lancet Diabetes & Endocrinology

Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X)

(2013) J. Rosenstock et al.   DIABETES CARE

Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia

(2013) J. Rosenstock et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1)

(2013) G. B. Bolli et al.   DIABETIC MEDICINE

Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial

(2013) B. Charbonnel et al.   DIABETOLOGIA

Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial

(2013) F. J. Lavalle-González et al.   DIABETOLOGIA

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

(2013) William T Cefalu et al.   LANCET

RETRACTED: Evaluation of the positive effects on insulin-resistance and β-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients

(2013) Giuseppe Derosa et al.   PHARMACOLOGICAL RESEARCH

The effects of excluding treatments from network meta-analyses: survey

(2013) E. J. Mills et al.   BMJ-British Medical Journal

Efficacy and safety of linagliptin 2.5 mg twice daily versus 5 mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial

(2012) Stuart A. Ross et al.   CURRENT MEDICAL RESEARCH AND OPINION

Reduction of Oxidative Stress and Inflammation by Blunting Daily Acute Glucose Fluctuations in Patients With Type 2 Diabetes: Role of dipeptidyl peptidase-IV inhibition

(2012) M. R. Rizzo et al.   DIABETES CARE

Dose-Ranging Effects of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-On to Metformin in Subjects With Type 2 Diabetes

(2012) J. Rosenstock et al.   DIABETES CARE

Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2012) S. E. Inzucchi et al.   DIABETES CARE

Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin

(2012) Ö. Ljunggren et al.   DIABETES OBESITY & METABOLISM

Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus

(2012) C. Pan et al.   DIABETES OBESITY & METABOLISM

Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients

(2012) Giuseppe Derosa et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes

(2012) G. Derosa et al.   DIABETIC MEDICINE

Efficacy and Tolerability of the DPP-4 Inhibitor Alogliptin Combined with Pioglitazone, in Metformin-Treated Patients with Type 2 Diabetes

(2012) R. A. DeFronzo et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial

(2012) Baptist Gallwitz et al.   LANCET

Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial

(2012) Pablo Aschner et al.   LANCET

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial

(2012) Baptist Gallwitz et al.   LANCET

Efficacy and Safety of Taspoglutide Versus Sitagliptin for Type 2 Diabetes Mellitus (T-Emerge 4 Trial)

(2012) Richard M. Bergenstal et al.   Diabetes Therapy

Effects of Acarbose Versus Glibenclamide on Glycemic Excursion and Oxidative Stress in Type 2 Diabetic Patients Inadequately Controlled by Metformin: A 24-Week, Randomized, Open-Label, Parallel-Group Comparison

(2011) Jun-Sing Wang et al.   CLINICAL THERAPEUTICS

Effectiveness of Lifestyle Interventions for Individuals With Severe Obesity and Type 2 Diabetes: Results from the Look AHEAD trial

(2011) J. L. Unick et al.   DIABETES CARE

Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin: A randomized, 52-week, double-blind, active-controlled noninferiority trial

(2011) M. A. Nauck et al.   DIABETES CARE

Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: A randomized controlled trial

(2011) Wenying Yang et al.   DIABETES RESEARCH AND CLINICAL PRACTICE

PIOfix-Study: Effects of Pioglitazone/Metformin Fixed Combination in Comparison with a Combination of Metformin with Glimepiride on Diabetic Dyslipidemia

(2011) Andreas Pfützner et al.   Diabetes Technology & Therapeutics

Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73 913 patients

(2011) Gianpaolo Reboldi et al.   JOURNAL OF HYPERTENSION

Conducting Indirect-Treatment-Comparison and Network-Meta-Analysis Studies: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 2

(2011) David C. Hoaglin et al.   VALUE IN HEALTH

Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial

(2010) R. Arechavaleta et al.   DIABETES OBESITY & METABOLISM

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study

(2010) M.-R. Taskinen et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

(2010) André J. Scheen et al.   DIABETES-METABOLISM RESEARCH AND REVIEWS

A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study

(2010) C. Filozof et al.   DIABETIC MEDICINE

Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial

(2010) B. Göke et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Effect of Noninsulin Antidiabetic Drugs Added to Metformin Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes

(2010) Olivia J. Phung   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

(2010) Clifford J Bailey et al.   LANCET

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

(2010) Richard E Pratley et al.   LANCET

The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone

(2009) R. A. DeFronzo et al.   DIABETES CARE

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

(2009) E. Ferrannini et al.   DIABETES OBESITY & METABOLISM

Effects of Colesevelam, Rosiglitazone, or Sitagliptin on Glycemic Control and Lipid Profile in Patients with Type 2 Diabetes Mellitus Inadequately Controlled by Metformin Monotherapy

(2009) Scott Rigby et al.   Endocrine Practice

Efficacy and Tolerability of Vildagliptin in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy

(2009) M. Goodman et al.   HORMONE AND METABOLIC RESEARCH

Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes

(2008) Itamar Raz et al.   CURRENT MEDICAL RESEARCH AND OPINION

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study

(2008) M. Nauck et al.   DIABETES CARE

Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes*

(2008) R. Scott et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

(2008) M. A. Nauck et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus—An effect probably mediated by direct platelet PPARγ activation

(2007) M.P. Khanolkar et al.   ATHEROSCLEROSIS

Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: A meta-analysis

(2007) Matteo Monami et al.   DIABETES RESEARCH AND CLINICAL PRACTICE